Retinoids for treatment of Alzheimer's disease

BioFactors

Volumn 38, Issue 2, 2012, Pages 84-89

  Lerner, Alan J ^a,b   Gustaw Rothenberg, Kasia ^a   Smyth, Shawn ^a   Casadesus, Gemma ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

All trans retinoic acid; Alzheimer's disease; Amyloid; Retinoids

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID; AMYLOID BETA PROTEIN; ETRETIN; ISOTRETINOIN; RETINOIC ACID; RETINOID; RETINOL DERIVATIVE; TAMIBAROTENE;

ACNE VULGARIS; ALZHEIMER DISEASE; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DRUG MECHANISM; HUMAN; NERVE FIBER GROWTH; NEUROBLASTOMA; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PSORIASIS; REVIEW;

ALZHEIMER DISEASE; ANIMALS; HUMANS; RETINOIDS; TRETINOIN; VITAMIN A;

EID: 84859419790     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.196     Document Type: Review

References (39)

1. Donato, R. ( 2003) Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 60, 540-551.
2. Marshak, D. R., Pesce, S. A., Stanley, L. C., Griffin, W. S. ( 1992) Increased S100 beta neurotrophic activity in Alzheimer's disease temporal lobe. Neurobiol. Aging 13, 1-7.
3. Selkoe, D. J. ( 2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065.
4. Lahiri, D. K., Farlow, M. R., Sambamurti, K., Greig, N. H., Giacobini, E., Schneider, L. S. ( 2003) A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 4, 97-112
5. Broytman, O. and Malter, J. S. ( 2004) Anti-Abeta: the good, the bad, and the unforeseen. J. Neurosci. Res. 75, 301-306.
6. Farooqui, A. A., Antony, P., Ong, W. Y., Horrocks, L. A., and Freysz, L. ( 2004) Retinoic acid-mediated phospholipase A2 signaling in the nucleus. Brain Res. Brain Res. Rev. 45, 179-195.
7. Achan, V., Tran, C. T., Arrigoni, F., Whitley, G. S., Leiper, J. M., and Vallance, P. ( 2002) All-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ. Res. 90, 764-769.
8. Corcoran, J. P., So, P. L., and Maden, M. ( 2004) Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur. J. Neurosci. 20, 896-902.
9. Mao, C. T., Li, T. Y., Liu, Y. X., and Qu, P. ( 2005) Effects of marginal vitamin A deficiency and intervention on learning and memory in young rats. Zhonghua Er Ke Za Zhi. 43, 526-530
10. Wolf, G. ( 2008) Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors. Nutr. Rev. 66, 55-59.
11. Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., and Yamada, M. ( 2004) Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp. Neurol. 189, 380-392
12. Takasaki, J., Ono, K., Yoshiike, Y., Hirohata, M., Ikeda, T., Morinaga, A., Takashima, A., and Yamada, M. ( 2011) Vitamin A has anti-oligomerization effects on amyloid-β in vitro. J. Alzheimers Dis. 27, 271-280.
13. Gilgun-Sherki, Y., Melamed, E., and Offen, D. ( 200) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40, 959-975.
14. Tippmann, F., Hundt, J., Schneider, A., Endres, K., Fahrenholz, F. ( 2009) Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB 23, 1643-1554.
15. Kawahara, K., Nishi, K., Suenobu, M., Ohtsuka, H., Maeda, A., Nagatomo, K., Kuniyasu, A., Staufenbiel, M., Nakagomi, M., Shudo, K., and Nakayama, H. ( 2009). Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain beta-amyloid peptides in APP23 mice. Biol. Pharm. Bull. 32, 1307-1309.
16. Lee, H.-P., Casadesus, G., Zhu, X., Lee, H.-G., Perry, G., Smith, M. A., Gustaw-Rothenberg, K., and Lerner, A. ( 2009) All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev. Neurotherapeut. 9, 1615-1621.
17. Shudo, K., Fukasawa, H., Nakagomi, M., and Yamagata, N. ( 2009) Towards retinoid therapy for Alzheimer's disease. Curr. Alzheimer Res. 6, 302-311.
18. Patatanian, E. and Thompson, D. F. ( 2008) Retinoic acid syndrome: a review. J. Clin. Pharm. Ther. 33, 331-338.
19. Herrup, K. and Arendt, T. ( 2002) Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. J. Alzheimers Dis. 4, 243-247.
20. Chen, J., Cohen, M. L., Lerner, A. J., Yang, Y., and Herrup, K. ( 2010) DNA damage and cell cycle events implicate cerebellar dentate nucleus neurons as targets of Alzheimer's disease. Mol. Neurodegener. 5, 60.
21. Gustaw, K. A., Casadesus, G., Friedland, R. P., and Smith, M. A. ( 2005) Georg Perry Cell cycle activation and the beta-amyloid protein in Alzheimer's disease. In Cell Cycle in the Central Nervous System ( Janigro, D., ed.). pp. 299-303, Humana Press, Totowa, NJ.
22. Moh, C., Kubiak, J. Z., Bajic, V. P., Zhu, X., Smith, M. A., and Lee, H. G. ( 2011) Cell cycle deregulation in the neurons of Alzheimer's disease. Results Probl. Cell Differ. 53, 565-76.
23. Endres, K., Postina, R., Schroeder, A., Mueller, U., and Fahrenholz, F. ( 2005) Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J. 272, 5808-5820.
24. Prinzen, C., Muller, U., Endres, K., Fahrenholz, F., and Postina, R. ( 2005) Genomic structure and functional characterization of the human ADAM10 promoter FASEB J. 19, 1522-1524.
25. Fahrenholz, F., Tippmann, F., and Endres, K. ( 2010) Retinoids as a perspective in treatment of Alzheimer's disease. Neurodegener. Dis. 7, 190-192
26. Zimmermann, M., Gardoni, F., Marcello, E., Colciaghi, F., Borroni, B., Padovani, A., Cattabeni, F., and Di Luca, M. ( 2004) Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 90, 1489-1499.
27. Goodman, A. B. ( 2006) Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J. Cell Physiol. 209, 598-603.
28. Wolf, G. ( 2010) Tissue-specific increases in endogenous all-trans retinoic acid: possible contributing factor in ethanol toxicity. Nutr. Rev. 68, 689-692.
29. Larsen, F. G., Jakobsen, P., Knudsen, J., Weismann, K., Kragballe, K., and Nielsen-Kudsk, F. ( 1993) Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J. Invest. Dermatol. 100, 623-627.
30. Almond-Roesler, B. and Orfanos, C. E. ( 1996) Trans-acitretin is metabolized back to etretinate. Importance for oral retinoid therapy. Hautarzt 47, 173-177.
31. Ding, Y., Qiao, A., Wang, Z., Goodwin, J. S., Lee, E. S., Block, M. L., Allsbrook, M., McDonald, M. P., and Fan, G. H. ( 2008) Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J. Neurosci. 28, 11622-11634.
32. Penniston, K. L. and Tanumihardjo, S. A. ( 2006) The acute and chronic toxic effects of vitamin A. Am. J. Clin. Nutr. 83, 191-201.
33. Goldschmidt, N., Gural, A., and Ben Yehuda, D. ( 2003) Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia. Leuk. Lymphoma 44, 1433-1437.
34. Larson, R. S. and Tallman, M. S. ( 2003) Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract. Res. Clin. Haematol. 16, 453-461.
35. Adamson, P. C, Matthay, K. K, O'Brien, M., Reaman, G. H., Sato, J. K., and Balis, F. M. ( 2007) A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: a Pediatric Oncology Branch, NCI and Children's Oncology Group Study. Pediatr. Blood Cancer 49, 661-665.
36. Green, R. C., Schneider, L. S., Amato, D. A., Beelen, A. P., Wilcock, G., Swabb, E. A., and Zavitz, K. H. Tarenflurbil Phase 3 Study Group. ( 2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
37. Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., and Aisen P. S. ( 2011) A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77, 556-563.
38. Fleisher, A. S., Truran, D., Mai, J. T., Langbaum, J. B., Aisen, P. S., Cummings, J. L., Jack, C. R. Jr., Weiner, M. W., Thomas, R. G., Schneider, L. S., and Tariot, P. N. ( 2011) Alzheimer's Disease Cooperative Study. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 77, 1263-1271.
39. Kang, M. R., Lee, S. W., Um, E., Kang, H. T., Hwang, E. S., Kim, E. J., and Um, S. J. ( 2010) Reciprocal roles of SIRT1 and SKIP in the regulation of RAR activity: implication in the retinoic acid-induced neuronal differentiation of P19 cells. Nucleic Acids Res. 38, 822-831.